Date: 2011-02-03
Type of information: Fundraising
Company: to-BBB (The Netherlands)
Investors: Jonghoud International BV (The Netherlands) - Industrial Bank of Taiwan Management Corporation (IBTM) (Taiwan) - Aescap Venture (The Netherlands) - Antea Participaties (The Netherlands)
Amount: €4 million
Funding type: Series B investment round
Planned used: These funds will enable to-BBB to enter the clinic with its brain cancer lead product before the summer and to develop other potential CNS therapies that utilize the company’s proprietary G-Technology® for brain drug delivery. With this new investment to-BBB will obtain important clinical validation for its G-Technology by performing a phase I/II study with its lead product 2B3-101. This product for multiple brain cancer types will initially be studied in patients with brain metastases of breast cancer. The study will start in Q2 2011 and is planned to treat 30 patients. Furthermore, the company will broaden the application of the G-Technology in several other CNS indications both internally and with partners.
Others: to-BBB Holding BV, the Dutch brain drug delivery company, has realized a first close of its Series?B investment round at €4 million. The company welcomes the Dutch Healthcare Investors of Jonghoud International BV and the Boston Life Science fund of the Industrial Bank of Taiwan Management Corporation (IBTM). The existing investors Aescap Venture and Antea Participaties also contributed to the round. This Series B round supplemented by additional non?dilutive (governmental) funding programs will support the company for two years to make these important value steps.
Therapeutic area: Cancer - Oncology
